🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementJoint pain improvement vs new joint pain — looking for input

Joint pain improvement vs new joint pain — looking for input

Dr.PeteFamMed Mon, Oct 27, 2025 at 2:56 PM 16 replies 1,432 viewsPage 1 of 4
This thread is more than 7 months old. Information may be outdated. Consider searching for more recent discussions.
Dr.PeteFamMed
Senior Member
2,012
9,234
Jan 2024
Minneapolis, MN
Oct 27, 2025 at 2:56 PM#1

Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

Trial-level incidence runs roughly 20 to 25% for nausea at the higher dose tiers and 12 to 17% for diarrhoea, with most events mild to moderate and concentrated in the weeks after each escalation.

The question I want answered is what distinguishes the nausea you can titrate through from the nausea that means stop.

Tell me what I have not thought of.

15 10hyun_seoul, jim_asheville, matt_MKE and 12 others
Reply Quote Save Share Report
Dr.MetabolicMD
VIP Member
2,345
16,789
Jan 2024
Rochester, MN
Oct 27, 2025 at 3:09 PM#2

Taking the question as asked, rather than the general version of it. The line between titrate-through and stop is not severity, it is trajectory and what else is present. Nausea that peaks and improves within a week is the expected pattern. Nausea that is escalating, or that comes with severe upper-abdominal pain radiating to the back, or that prevents fluids for more than a day, is a different conversation and belongs with a clinician the same day.

14 9PedsEndoPhilly, SleepDoc_PDX, RegAffairsDC and 11 others
Reply Quote Save Share Report
zoe_NC
Member
278
1,234
Nov 2024
Charlotte, NC
Oct 27, 2025 at 3:22 PM#3
Dr.MetabolicMD said:
The line between titrate-through and stop is not severity, it is trajectory and what else is present.

Agreed on adaptation, with a caveat: adaptation applies to gastric emptying and not to everything. If your problem is the aversion rather than the fullness, waiting does less, because the aversion is central and it is the mechanism working as intended.

13 8james_edin, FranDenver, Dr.BariatricHTX and 10 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
bbq_ray_KC
Member
378
1,678
Jul 2024
Kansas City, KS
Oct 27, 2025 at 3:35 PM#4
Dr.PeteFamMed said:
Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

Same position here, arrived at the long way round. The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the fat fraction of meals in the two days after dosing, and do not lie down straight after eating. Most of what people call unmanageable nausea is a meal-size and meal-composition problem interacting with a stomach that is emptying slowly.

Last edited: Oct 27, 2025 at 5:35 PM
12 7WendyG_ATL, SaraMom3, Dr.MetabolicMD and 9 others
Reply Quote Save Share Report
EndoResFellow
Member
456
2,345
Sep 2024
Baltimore, MD
Oct 27, 2025 at 4:43 PM#5

Clinical perspective, offered as context rather than as advice. If two explanations both fit, the useful question is which one predicts something the other does not. That is answerable; arguing about which sounds more plausible is not.

Last edited: Oct 27, 2025 at 6:43 PM
11 6Dr.ObesityLA, NurseKim_ATL, paul_denver and 8 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register